Clinical stage oncology company Prescient Therapeutics (ASX:PTX) is heading to market with a capital raising, and the ASX has granted the company a trading halt to prepare.
The company is developing novel compounds that show promise as potential new therapies to treat a range of cancers that have become resistant to front line chemotherapy.
Lead drug candidate PTX-200 inhibits an important tumor survival pathway known as AKT, which plays a key role in the development of many cancers.
The halt will remain in place until the opening of trade on Friday 30th October 2015, or earlier if an announcement is made to the market.
Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX emerging companies with distribution in Australia, UK, North America and Hong Kong / China.